Skip to main content

Better Outcomes With Vein- vs Artery-First Procedure During Lung Cancer Surgery

Ligation of effluent veins as the first step during operation may be more in line with cancer treatment ethics and should be recommended for patients undergoing lung cancer surgery, according to investigators in a recent study (JAMA Surg. 2019 May 1. Epub ahead of print).

“It is important to develop a surgical technique to reduce dissemination of tumor cells into the blood during surgery,” according to Shiyou Wei, MD, Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China, and colleagues.

Seeking to evaluate and compare the outcomes of different vessel ligation sequences during surgery on tumor cell dissemination and survival in patients with non–small-cell lung cancer (NSCLC), Dr Wei et al conducted a multi-center clinical trial was conducted of patients with NSCLC receiving thoracoscopic lobectomy at 1 of 3 Chinese hospitals.

Between December 2016 and March 2018, a total of 86 patients were enrolled and randomized to undergo a vein- or artery-first procedure.

“To further compare survival outcomes of the 2 procedures, we reviewed the Western China Lung Cancer database (2005-2017) using the same inclusion criteria,” Dr Wei and colleagues said.

The main end points of the study were changes in folate receptor–positive circulating tumor cells (CTCs) postsurgery, and rates of 5-year overall, disease-free, and lung cancer-specific survival.

Ultimately, 78 of the patients included in the study were analyzed. After surgery, the investigators observed an incremental change in folate receptor–positive CTCs in 26 (65.0%) of 40 patients in the artery-first arm and 12 (31.6%) of 38 patients in the vein-first arm (P = .003; median change, 0.73 FU per 3 mL vs -0.50 FU per 3 mL; P = .006).

Using a multivariate analysis, the researchers confirmed the artery-first procedure as a risk factor for increase in folate receptor–positive CTC during surgery (hazard ratio [HR], 4.03; 95% CI, 1.53-10.63; P = .005).

A total of 420 patients (210 with vein-first and 210 with artery-first procedures) were included in the propensity-matched analysis. Patients in the vein-first arm had significantly better outcomes than those in the artery-first arm with regard to 5-year overall (73.6%; 95% CI, 64.4%-82.8% vs 57.6%; 95% CI, 48.4%-66.8%; P = .002), disease-free (63.6%; 95% CI, 55.4%-73.8% vs 48.4%; 95% CI, 40.0%-56.8%; P = .001), and lung cancer-specific (76.4%; 95% CI, 67.6%-85.2% vs 59.9%; 95% CI, 50.5%-69.3%; P = .002) survival rates.

Notably, the artery-first procedure was a prognostic factor of poorer 5-year overall (HR, 1.65; 95% CI, 1.07-2.56; P = .03), disease-free (HR, 1.43; 95% CI, 1.01-2.04; P = .05) and lung cancer-specific (HR = 1.65; 95% CI, 1.04-2.61; P = .03) survival, according to multivariate analyses.

“Ligating effluent veins first during surgery may reduce tumor cell dissemination and improve survival outcomes in patients with non-small cell lung cancer,” Dr Wei et al concluded.—Hina Khaliq